TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25638303
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg twice daily (BID)
Study: 24296323
Drug: Etamicastat 50
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 50 mg
Study: 24296323
Drug: Etamicastat 100
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 100 mg
Study: 24296323
Drug: Etamicastat 200
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 200 mg
Study: 16597501
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control group, n=30)
Study: 16597501
Drug: Carbamazepine monotherapy
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine monotherapy (following open-label treatment)
Study: 29515151
Drug: Rectal swab
Normalized name: witch hazel .5 mL RECTAL SWAB [Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal swab samples
Study: 27832025
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg valacyclovir twice daily
Study: 28319423
Drug: Silexan 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 160 mg/d
Study: 28319423
Drug: Silexan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 80 mg/d
Study: 15531007
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/d
Study: 15167707
Drug: Interferon-alpha2 (IFN-alpha2)
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2 (IFN-alpha2) treatment
Study: 11259325
Drug: Oral nateglinide
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nateglinide (120 mg)
Study: 11259325
Drug: Intravenous nateglinide
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nateglinide (60 mg)
Study: 31654943
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter defibrillator (S‐ICD)
Study: 19562533
Drug: iv paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv paracetamol 1 g preoperatively (Group I)
Study: 19562533
Drug: iv paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv paracetamol 1 g intraoperatively (Group II)
Study: 17659757
Drug: Azathioprine with
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine with methylprednisolone (AZA) treatment for 24 months
Study: 9595977
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (6 MIU, 30 microg) administered via single intramuscular injection
Study: 9595977
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (6 MIU, 30 microg) administered in the placebo-controlled phase III clinical trial
Study: 23237936
Drug: Furosemide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.3 mg/kg) combined with mannitol (1 g/kg)
Study: 16687991
Drug: Placebo (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (during discontinuation phase)
Study: 12453926
Drug: Morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.15 mg kg(‐1)
Study: 15504188
Drug: Midazolam 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.30 mg kg(‐1)
Study: 7707164
Drug: Short-acting ACE
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting ACE inhibitors (captopril and quinapril) given twice a day
Study: 7707164
Drug: Long-acting ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting ACE inhibitors (enalapril, lisinopril, benazepril, cilazapril) given once a day
Study: 904549
Drug: 0.15 g
Normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g phenformin/day
Study: 25963481
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pradigastat with a low-fat meal
Study: 25963481
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pradigastat with a high-fat meal
Study: 25963481
Drug: Fasted or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted or fed conditions (both 20 and 40 mg doses)
Study: 21640879
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with fixed appliances (bands and brackets)
Study: 20110014
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 37.5 mg tablets (study A)
Study: 20110014
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75 mg tablets (study B)
Study: 16304557
Drug: alfuzosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin (10 or 15 mg) once daily for 3 months
Study: 2576327
Drug: Theophylline and
Normalized name: theophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline and beta-adrenergic agonists combination
Study: 1119820
Drug: 1.0% colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% colchicine in hydrophilic ointment applied once daily for 6 to 12 weeks
Study: 31202270
Drug: Blended psychosocial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended psychosocial support program based on Acceptance and Commitment Therapy
Study: 26314902
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg (2 hours prior to induction)
Study: 23351633
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g of farmed Atlantic salmon, twice per week for 4 weeks
Study: 15259285
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (two tablets of an extract of aglycone isoflavones from red clover for 6 months)
Study: 11284785
Drug: 3 or
Normalized name: Cytra-3 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 or 5 MU IFN‐alpha daily for 1 month, followed by the same dose three times a week for 11 months
Study: 26423649
Drug: Ongoing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing triple therapy (OT)
Study: 26986803
Drug: Ritonavir-boosted PI
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted PI monotherapy (PI-mono)
Study: 23297506
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 0.2 g bid for 4‐6 weeks and oral Terazosin at 2 mg qd for 2 months
Study: 18611339
Drug: Modified regime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified regime with epinephrine (K=1 mg) and aminophylline (7 mg/kg)
Study: 18611339
Drug: Modified regime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified regime with epinephrine (K=2 mg) and aminophylline (7 mg/kg)
Study: 18611339
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with standard epinephrine treatment (1 mg every 3 minutes if no effect)
Study: 24606096
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment
Study: 9280254
Drug: Resovist (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resovist (all doses)
Study: 1952999
Drug: 30 U/m2/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 U/m2/week growth hormone treatment
Study: 1952999
Drug: 15 U/m2/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 U/m2/week growth hormone treatment
Study: 30755256
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (tTXA)
Study: 25053129
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with preleukapheresis IFN-α (3 MU subcutaneous for 7 days)
Study: 17355587
Drug: Intensive medication
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medication management (MedMgt)
Study: 17355587
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (with or without medication)
Study: 14998110
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care (CC)
Study: 14749863
Drug: 2.5% arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% arginine hydrochloride ointment
Study: 11176663
Drug: Minocycline, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline, 200 mg/d for a median duration of 12 months
Study: 9923586
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (various classes including diuretics, beta blocking agents, calcium channel blockers, ACE inhibitors, hypotensives)
Study: 9923586
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and diuretics
Study: 9923586
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (diuretic with beta blocking agent)
Study: 11566623
Drug: Interleukin-2 therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 therapy
Study: 29943744
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin D supplementation
Study: 23153410
Drug: Post-prescription review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-prescription review by the infectious disease physician (IDP)
Study: 19048842
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with melatonin
Study: 27974224
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (treatment and control)
Study: 8498949
Drug: Levonorgestrel-containing pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-containing pill
Study: 30843767
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day milled flaxseed for 12 weeks
Study: 31689127
Drug: Dermalax injection
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermalax injection
Study: 31689127
Drug: Restylane injection
Normalized name: Restylane
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane injection
Study: 28701670
Drug: Compound Hypertonic
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Hypertonic Saline Solution (C‐HSS) with high dose furosemide (100 mg) plus C‐HSS (100 mL) twice daily
Study: 28701670
Drug: Furosemide intravenous
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide intravenous bolus (100 mg) twice a day without C‐HSS
Study: 20875370
Drug: Ticagrelor 900
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 900 mg
Study: 15463871
Drug: Nebulised rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised rhDNase (2.5 mg)
Study: 15463871
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% (10 ml)
Study: 31676515
Drug: Gauze and
Normalized name: tubular gauze and rubber dressing protector (fingers, toes) 7/8" X 9" TOPICAL BANDAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gauze and tape dressing changed once daily
Study: 15749623
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein diet (25 g soy/4.2 MJ)
Study: 15749623
Drug: Isoflavone diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone diet (50 mg isoflavones/4.2 MJ)
Study: 11927473
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia with rocuronium (0.5 mg/kg at induction, followed by 0.3 mg/kg one hour later)
Study: 11764012
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg triazolam
Study: 28972191
Drug: Daily acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily acute intermittent hypoxia (AIH) + hand opening practice
Study: 19672601
Drug: Body Awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Awareness Therapy
Study: 16876249
Drug: VEGF Trap
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap 0.3 mg/kg
Study: 16876249
Drug: VEGF Trap
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap 1.0 mg/kg
Study: 16876249
Drug: VEGF Trap
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap 3.0 mg/kg
Study: 12152639
Drug: Laparoscopic transabdominal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic transabdominal preperitoneal patch technique (TAPP)
Study: 10200011
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aerosol 88 microg twice daily
Study: 10200011
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aerosol 220 microg twice daily
Study: 10200011
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol 200 microg 4 times daily
Study: 10200011
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol 400 microg twice daily
Study: 8153939
Drug: Prednisone 10
Normalized name: prednisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 mg once daily
Study: 1977869
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (2.5‐3.0 g/kg), high calorie (BEE x 1.2 x 1.6) diet
Study: 1977869
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (1‐1.5 g/kg), normal calorie (30‐35 Kcal/kg) diet
Study: 21762871
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.6 g/day of long-chain ω-3 fatty acids)
Study: 30860197
Drug: Short-stay protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-stay protocol (ambulated and graded oral intake initiated from 6 h post-operation, urethral catheters discontinued at 12 h, discharged on the 3rd day post-op)
Study: 30860197
Drug: Traditional protocol
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional protocol (ambulated from 12 h, graded oral intake initiated at 24 h, urethral catheters removed at 24 h, discharged on the 5th day post-op)
Study: 15031565
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with slightly elevated CRP levels (> or =1.8 mg/l)
Study: 9690059
Drug: Outpatient structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient structured diabetes treatment and teaching programme (DTTP)
Study: 29091516
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg once daily (n = 268)
Study: 26634593
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) at dosage of 4000 UI
Study: 19563193
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus Chinese medicine (group ACUP+CM)
Study: 19563193
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (group CM)
Study: 18705976
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (folic acid 2 mg, B(6) 25 mg, B(12) 500 microg)
Study: 3136954
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg t-PA over 6 hours
Study: 3136954
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg t-PA over 6 hours
Study: 24283931
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly or twice weekly for 12 weeks
Study: 28900875
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly for 24 weeks
Study: 29373701
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment
Study: 18171701
Drug: Synthetic L-T3
Normalized name: L-T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic L-T3 infusion (initial dose: 20 microg/m(2) body surface.d)
Study: 16829189
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment directed by plasma NTproBNP
Study: 1290244
Drug: Oral hydrolytic
Normalized name: THICK & EASY HYDROLYTE (HONEY) ORAL LIQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrolytic enzymes
Study: 1290244
Drug: Oral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gold salts
Study: 6207731
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon treatment for adenoviral conjunctivitis
Study: 6207731
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for adenoviral conjunctivitis
Study: 30036516
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate 20 mEq twice daily
Study: 27765184
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/day for 6 months
Study: 17332474
Drug: Meal A
Normalized name: Yardley Oatmeal and Almond Bath Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal A (500-ml 15% oil emulsion with 2.5% stable emulsifier)
Study: 17332474
Drug: Meal B
Normalized name: ameal bp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal B (500-ml 15% oil emulsion with 2.5% unstable emulsifier)
Study: 11486635
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aspirin + 50 mg caffeine
Study: 11486635
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg aspirin + 0 mg caffeine
Study: 11486635
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg aspirin + 50 mg caffeine
Study: 11486635
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg aspirin + 100 mg caffeine
Study: 29624723
Drug: RT001 (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT001 (1.8 or 9.0 g/day)
Study: 24660674
Drug: Coordinated Anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated Anxiety Learning and Management (CALM) intervention (CBT, medication, or both)
Study: 20632490
Drug: Autogenous PRP
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous PRP gel with acellular xenogeneic dermal matrix (PRP group)
Study: 17547800
Drug: Enoxaparin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.75 mg/kg) intra-arterially before PCI, with a possible supplement of 0.3 mg/kg if procedural time > 90 minutes.
Study: 12228782
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy before planned angioplasty
Study: 10190761
Drug: 0.1% naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% naproxen ophthalmic solution
Study: 10190761
Drug: 0.2% naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% naproxen ophthalmic solution
Study: 27572248
Drug: L-selenomethionine 166
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selenomethionine 166 µg/die
Study: 22683257
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (Antox version 1.2, Pharma Nord, Morpeth, UK)
Study: 22683257
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets, 3 times/day)
Study: 26037286
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy alone
Study: 12209041
Drug: Etoricoxib 5
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 5 mg q.d.
Study: 12209041
Drug: Etoricoxib 10
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 10 mg q.d.
Study: 12209041
Drug: Etoricoxib 30
Normalized name: Etoricoxib 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 30 mg q.d.
Study: 7828793
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg b.i.d.)
Study: 9825197
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg b.i.d.)
Study: 217894
Drug: HMG 2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG 2250 mg per day
Study: 217894
Drug: HMG 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG 3000 mg per day